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Materials and Methods: The study was
conducted from December 2011 to
December 2012 on 95 patients between the ages of 20 and
65 years: 44 of which had been undergoing dialysis for over
a year and 51 of whom had undergone kidney transplants
more than 6 months before. Comorbidities were carefully
recorded, erectile function was evaluated the with IIEF5
questionnaire and serum levels of total testosterone / free
and prolactin were tested at early morning (7 AM). To
assess the relationship between erectile dysfunction (ED)
and clinical laboratory tests, Student's t-test statistical
(quantitative variables), chi-square (qualitative variables),
the uni and multivariate analysis were used.
Results: In patients undergoing dialysis and in recently
transplanted patients a higher instance of ED was found
(70% and 65% of cases respectively). Amongst dialyzed
patients, patients aged over 50 suffer from ED more fre-
quently. Patients aged over 50s represent 61% of the total
number of patients suffering from ED, and just 31% of
patients not suffering from ED, (p = 0.006);
Hyperprolactinemia was found in 23% and 20% of both
groups respectively. Fifty nine % of the dialyzed patients
presented values of testosterone serum levels of  less than
250 ng/dl with a significant difference between those who
were suffering from ED and those who were not (65% of ED
patients vs. 46%,of patients not affected from ED p = 0.019).
This was found in only 37% of transplanted patients and
there does not appear to be a statistically significant correla-
tion with the onset of ED (p = 0.12). In patients over the age
of 50, diabetes and a condition of hypotestosteronemia were
significantly correlated with ED at univariate and multivari-
ate analyses. 
Conclusions: The ED in patients with end stage chronic kid-
ney failure (CKF) continues to have a strong prevalence,
either in the patients who are undergoing dialysis or in those
who have received transplants. In literature this issue is not
sufficiently considered if not at all. Hypotestosteronemia is a
risk factor for the onset of ED in end stage CKF patients. A
significantly lower prevalence of hypogonadism among dia-
lyzed patents and transplant recipients suggests that renal
transplantation may be protective for the sexual capabilities
of these patients.
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INTRODUCTION
Patients with end-stage chronic kidney failure (CKF) who
undergo hemodialysis experience a significant deteriora-
tion in their quality of life, due both to a treatment requir-
ing patients to attend dialysis sessions of 3-4 hours dura-
tion 3 days a week, and for the comorbidity associated
with it. Among comorbidities, it is important to highlight
erectile dysfunction due to its high frequency. In 1975,
the first scientific studies documenting a close link
between erectile dysfunction and chronic renal failure
came to light (1). Erectile dysfunction (ED) is an inabili-
ty to obtain or maintain an erection sufficient for satisfac-
tory sexual activity. With the examination of several stud-
ies, its prevalence in this group of patients becomes
apparent with a leveling off between 50 and 80% (1, 2).
Several factors may contribute to the onset of erectile dys-
function and its progression over time. These could
include: abnormalities in the neuro-endocrine control
system of the hypothalamic-pituitary-gonadal axis; sec-
ondary hyperparathyroidism; peripheral neuropathy;
changes in smooth muscle of the corpora cavernosa of the
penis, structural alterations of the arterial wall, damage of
the veno-occlusive cavernosal mechanism, drug therapies
consequential to CKF, stress and depression. 
Pathophysiology of erectile dysfunction 
in chronic renal failure
Numerous scientific evidence shows that the pulsatile
release of gonadotrophic hormones in uremic patients is
dramatically compromised until reaching a stage of clear
hypogonadism (3). 
In the plasma of patients with severe CKF, a decrease in
the concentration of testosterone and increased levels of
FSH and LH it is often noted (4). The decrease of con-
centration of testosterone in plasma is attributed to sev-
eral mechanisms: increased testosterone excretion dur-
ing the dialysis treatment (5), reduction of its production
by the Leydig cells (6), poor response to gonadotropin
stimulation probably induced, at least in part, by
cytokine changes resulting from the chronic systemic
disease. Low levels of testosterone stimulate a feedback
mechanism with the secretion of LH, whose concentra-
tion is further elevated as a result of its reduced renal
excretion. FSH levels are high because of the atrophy of
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the Sertoli cells, normally responsible for its inhibition
through the secretion of inhibin peptide (7). 
Hyperprolactinemia was present in 25-57% of male
patients with CKF and was indicated by some authors as
a possible associated cause of impotence, hypogonadism
and decreased libido (8). Hyperprolactinemia interferes
with normal gonadal response to gonadotropins, thus
resulting in a reduction in testicular steroidogenesis. The
reasons for the occurence of this remain disputed.
Erectile dysfunction may, however, be the earliest clinical
manifestation of diabetes based on autonomic neuropa-
thy. Diabetes is in fact the most frequent factor which
determines a condition of end-stage chronic renal failure.
Studies of tissue biopsy samples of uremic patients with
diabetes and erectile dysfunction documented a weaken-
ing of neurogenic and endothelial mechanisms that
allows the relaxation of smooth muscles of the corpora
cavernosa (9). In those patients the simultaneous diag-
nosis of neurogenic bladder supports a neuropathic eti-
ology of erectile dysfunction (10). The peripheral neu-
ropathies are the most frequent, in particular a sensory-
motor polyneuropathy that appears with numbness,
burning pain, and a reduction or disappearance of deep
tendon reflexes. Restless legs syndrome is frequent, char-
acterized by continuous movement of the legs during
sleep and caused by impaired neuromuscular conduc-
tion velocity. The autonomic nervous system may also be
compromised, leading to alterations in blood pressure
control and erectile dysfunction on a neuropathic basis.
The basis of the neuropathy is probably a block of nerve
transmission mediated by so-called “uremic toxins” (urea,
creatinine, parathyroid hormone, myoinositol and b2-
microglobulin). In particular, some substances with a
molecular weight between 300 and 12,000 Dalton are
suspected of being responsible for the neuropathy.
Studies have also shown a slowing of nerve conduction
in the segments not affected clinically. In patients with
chronic kidney disease an abnormal metabolism of car-
bohydrates, lipids and proteins is often observed. Due to
these reasons, and also to the state of inflammation that
accompanies the chronic kidney diseases, the uremic
patient is particularly predisposed to atherosclerosis and
therefore to ischemic disease especially in the coronary
artery, but also in the arterial penile district, determining
an artery based erectile dysfunction. 
Diabetes together with hypertension, another condition
extremely common in dialyzed patients, often deter-
mines a significant acceleration of atherosclerotic
processes and therefore a vascular based erectile dys-
function (11). In a large proportion of end-stage CKF
patients (78%), in fact, an occlusion was found in blood
vessels in the pelvic arteries and their tributaries (12).
A high percentage of patients with CKF, due to the occur-
rence of cardiovascular comorbidities, take medications
such as beta-blockers and diuretics whose most common
side effect is erectile dysfunction. but, replacing it with
other types of drugs does not appear to result in signifi-
cant improvements of erectile function (13). An impaired
synthesis of erythropoietin, very common in end-stage
CKF patients, as is well known, produces anemia, caus-
ing, among other side effects, a low flow of oxygen in the
corpora cavernosa; this results in a reduced synthesis of
nitric oxide and increased production of contractile fac-
tors of endothelial origin, leading to an augmentation of
smooth muscle tone and consequently a possible impair-
ment of the mechanism of erection (14). Finally, the psy-
chogenic component must not be ignored since patients
on dialysis often suffer from anxiety, low self-esteem and
chronic fatigue: these factors can lead to a reduction in
sexual interest (15, 16). Due to all of the aforementioned
possibilities, it is not surprising that the prevalence rate
of erectile dysfunction in dialyzed patients could be as
high as 80%. In kidney transplanted patients, the preva-
lence of erectile dysfunction remains high, occurring in
around 65% of cases and hypogonadism is also a fre-
quent occurrence. The protracted uremic condition
before the transplant is not only due to a functional dam-
age but also to an anatomical damage to the delicate
hypothalamic-pituitary-gonadal axis (17, 18). Biopsies
performed on transplanted patients in testicular tissue,
showed abnormalities of number and morphology of
Leydig cells (17). Other authors, instead, have focused
their attention on immunosuppressive therapy: a study
by Lee showed that the sirolimus (an immunosuppres-
sant drug often used in combination with calcineurin
inhibitors in renal transplant) results in a significant
decrease in serum concentrations of testosterone (18). It
was also postulated that the cyclosporin forms adversely
affect the production of nitric oxide, an essential sub-
strate in the complex mechanism of erection (19). So it
is possible that the immunosuppressive therapy in trans-
plant patients helps to maintain the endothelial and
gonadic dysfunction that the previous uremic state had
produced. A final possible explanation for the ED in the
transplanted patients is related to surgical transplant pro-
cedures: according to a study published by El-
Bahnasawy one internal iliac artery ligation without fur-
ther external iliac artery terminal anastomosis results in
a significant reduction of blood flow, negatively impact-
ing penile erectile function (20). 
Objective
The objectives of this study are as follows:
– The evaluation of the prevalence of sexual dysfunction
(erectile dysfunction and hypogonadism) in male
patients with end stage chronic renal failure on
hemodialysis; 
– The evaluation of the prevalence of sexual dysfunction
(erectile dysfunction and hypogonadism) in male
patients with end stage renal failure after kidney trans-
plantation; 
– The searching for factors predisposing to erectile dys-
function, with particular attention to hormones, in
male patients with end stage chronic renal failure, on
dialysis or after renal transplantation. 
MATERIALS AND METHODS
The study was conducted during the period between
December 2010 to December 2011, at the University
Hospital A. Gemelli, in the Department of Urology,
Department of Transplant Surgery and Center for
Hemodialysis. It involved a total of 95 patients aged
between 20 and 65 years with severe chronic renal fail-
ure, divided into two groups: one group of 44 patients
who had been undergoing dialysis for more than a year
and another consisting of 51 patients that recevied a
kideny transplant more than 6 months before. Clinical
information for patients in both groups was recorded
(age, start of dialysis treatment/duration of transplanta-
tion, pathology that led to the CKF, comorbidity, drug
treatment). All patients were given IIEF5 questionnaire,
consisting of 5 questions. This was proposed by Rosen in
1997 and is widely known and used for the evaluation of
the degree of erectile dysfunction (ED) (21). The score is
recorded between a range of 2 and 30. Four categories
can be identified depending on the score: the absence of
disease (score 26-30), mild ED (17-25), moderate ED
(11-16), severe ED (< 10). The study considered all
patients with ED with a score less than or equal to 25.
We also performed a blood test on all patients in order to
measure total and free testosterone and prolactin. A nor-
mal range of prolactin was defined as 3.5-15.5 ng/ml;
from 2.50 to 8.4 ng/ml for total testosterone; from 2.50
to 8.4 ng/ml for free testosterone. 
An informed consent was obtained from all patients. 
Statistical analysis
For both groups we calculated the prevalence of hypogo-
nadism and ED, which was in turn stratified by age and
severity. Then, within the two groups (post-dialysis and
transplant patients), some clinical features were compared
along with laboratory records among patients presenting
ED and those who did not presented it. The statistical rela-
tionships between ED and clinical-laboratory characteris-
tics were evaluated with Student t test for
quantitative variables and chi-square test for
qualitative variables. A p value < 0.05 was
considered statistically significant. Only
those statistically significant factors at uni-
variate analysis were further studied in a
multivariate analysis. Statistical analysis was
performed using the SPSS 14.0 system. 
RESULTS
In the group of dialyzed patients 44 men in
total were recruited, the average age of the
sample was 49 years. The ED was found in
31 patients, representing 70% of the sample.
Of these patients 7 (16%) reported mild ED,
10 (22%) moderate ED, and 14 (32%) severe
ED (Figure 1).
Patients older than 50 represent 61% of the
total number of patients suffering from ED
while representing just 31% of patients not
suffering from ED, p = 0.006. There is also
a high prevalence of diabetes in those who
suffer from ED compared with those who
do not (39% of the total number of patients
suffering from ED versus 15%,of the total
number of patients not suffering, p =
0.014). The other clinical characteristics
(duration of dialysis, use of beta-blockers),
although presenting minimal difference
between the two subgroups examined, do
not reach the threshold of statistical significance. Among
the laboratory parameters, hyperprolactinemia is present
in 23% of patients, but without significant differences
between the two subgroups. With regard to testosterone,
as many as 59% of the patients had serum values below
250 ng/dl with a significant difference between those suf-
fering from ED and those not (65% of the total number
of patients suffering from ED versus 46%,of the total
number of patients not suffering, p = 0.019) (Table 1).
Among the considered factors, those which significantly
correlated with ED based on a univariate analysis were the
following: being older than 50 years of age, diabetes and a
condition of hypotestosteronemia. These considerations
are confirmed after a multivariate analysis (Table 2). 
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Figure 1. 
Prevalence of ED in patients with CKF on dialysis.
Clinical-laboratory Total patients Patients with ED Patients without ED p
characteristics n = 44 n = 31 n = 13 
Age > 50 years 23 (52%) 19 (61% of ED 4 (31% of no-ED 0.006 
patients) patients)
Diabetes 14 (31%) 12 (39% of ED 2 (15% of no-ED 0.014
patients) patients)
Duration of dialysis 
in months * 65.2 (52.4) 63.1 (50.9) 67.3 (54.3) 0.72
Taking beta-blockers 33 (75%) 24 (77% of ED 9 (69% of no-ED 0.66
patients) patients)
Hypotestosteronemia 26 (59%) 20 (65% of ED 6 (46% of no-ED 0.019
(Free T < 40 pg/ml) patients) patients)
Hyperprolactinemia 11 (25%) 8 (26% of ED 3 (23% of no-ED 0.53
(PRL > 15.5 ng/ml) patients) patients)
* Standard deviation in brackets.
Table 1. 
Clinical and laboratory characteristics of the sample.
Risk factors for ED OR IC 95% p
Age > 50 years 7.221 1.826 to 29.385 0.004
Diabetes 6.139 1.298 to 31.659 0.023
Hypotestosteronemia (fT < 40 pg/ml) 6.456 1.437 to 40.871 0.031
OR: odds ratio; IC: interval confidence 95%.
Table 2. 
Results of multivariate analysis for risk factors for ED in patients 
with CKF on dialysis.
Severe (2-10)
32%
Absent (IIEF 5: 26-30)
29%
Mild (17-25)
16%Moderate (11-16)
23%
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In the group of 51 patients with end stage CKF, who
received renal transplantation from over a year, the aver-
age age stood at 47 years, DE was found in 33 patients
(65%). Out of them in 9 (18%) DE proved to be mild, in
10 (20%) moderate ED and in 14 (27%) severe ED
(Figure 2). 
Through the evaluation of the clinical and laboratory
characteristics of this second group of patients, it
becomes clear that in the cases older than 50 years of age
(51% of the sample) there is a significant risk factor for
the emergence of ED. There are 22 (67%) who are over
fifty, while in this subgroup four are not affected,
accounting for only 22% (p = 0.004). Diabetes, that in
the dialysis group continues to be a statistically signifi-
cant factor for the onset of ED (p = 0.01),
seems to play a significant role in the
etiopathogenesis of ED in post-transplant,
that did not depend on duration of trans-
plantation and the possible use of beta-
blockers. Turning to the evaluation of the
hormone profile, hyperprolactinemia was
present in 20% of the sample without sig-
nificant differences between the two sub-
groups. However the most interesting result
is that relative to the hypotestosteronemia
which is predicated on having a prevalence
of less than or equal to the group of dialysis
37% and also does not appear statistically
significant correlated with the onset of ED
(p = 0.12) (Table 3). 
Age > 50 years and diabetes remain as the
only statistically significant risk factors for the
onset of ED in the group of transplant
patients. The data was also confirmed after
performing a 'multivariate analysis (Table 4). 
DISCUSSION
Erectile dysfunction in patients treated with
dialysis for end-stage chronic kidney failure
has a particularly high prevalence. The first
epidemiological studies have been carried
on since the early 70's by Abram (22). Over
the years many others have been conducted,
including Fletcher’s (23), all of which indicated a preva-
lence rate above 50%, varying between 63% and 81%. In
our study the prevalence of ED amongst patients on dial-
ysis amounted to 70%. 
This shows that despite the clear improvement of thera-
py for end-stage kidney failure over the years, the preva-
lence of ED has remained high. Age was always consid-
ered as the major risk factor for the onset of ED and the
concept is also valid for the patients on dialysis .In our
study the mean age of patients without ED stands at 43
years. On the other hand, the average age is 54 in
patients with ED. In this study therefore, patients over
fifty have a 7.2 times greater risk of developing ED than
younger individuals. However, if the data obtained in
this study were to be compared with the data from other
studies, in a sample of individuals in apparent good
health, the average age of onset of ED is 5 years lower (54
vs 59 years) and severe forms of ED are 50% more.
Therefore the end-stage chronic renal failure has to be
considered a factor that accelerates and exacerbates the
pathological mechanisms responsible for the appearance
of ED that develops normally with age. 
In our study, as previously published (24), another sig-
nificant risk factor is diabetes, which is the cause that
leads a kidney disease patient to dialysis, and also the
main responsible for the onset of ED. It is important to
point out that diabetes is able to determine the onset of
ED regardless of the presence or absence of diabetic
nephropathy. In patients with end-stage CRF and dia-
betes, it is still uncertain whether the ED appears before
or after the beginning of dialysis treatment. 
With regard to the duration of dialysis treatment in our
Clinical-laboratory Total patients Patients with ED Patients without ED p
characteristics n = 51 n = 33 n = 18 
Age > 50 years 26 (51%) 22 (61% of ED 4 (22% of no-ED 0.004
patients) patients)
Diabetes 15 (29%) 13 (39% of ED 2 (11% of no-ED 0.010
patients) patients)
Duration of   
transplantation in years * 7.2 (5.6) 7.4 (5.9) 7.0 (5.4) 0.82
Taking beta-blockers 35 (69%) 24 (72% of ED 11 (61% of no-ED 0.57
patients) patients)
Hypotestosteronemia 19 (37%) 13 (39% of ED 6 (33% of no-ED 0.012
(Free T < 40 pg/ml) patients) patients)
Hyperprolactinemia 10 (20%) 7 (21% of ED 3 (17% of no-ED 0.36
(PRL> 15.5 ng/ml) patients) patients)
* Standard deviation in brackets.
Table 3. 
Characteristics of clinical laboratory sample.
Risk factors for ED OR IC 95% p
Age> 50 years 7.823 1.724 to 26.384 0.005
Diabetes 6.755 1.128 to 30.054 0.019
OR: Odds ratio; IC: interval confidence 95%.
Table 4. 
Results of multivariate analysis for risk factors for ED in CRF patients
after kidney transplantation.
Figure 2. 
Prevalence of ED in CKF patients after kidney
transplantation.
Severe (2-10)
27%
Absent (IIEF 5: 26-30)
35%
Mild (17-25)
18%
Moderate (11-16)
20%
study, it affects neither the appearance nor the develop-
ment of ED. This conclusion is supported by numerous
studies in the literature (25). There is, however, a
prospective study carried out by Capotondo in 1990,
which shows an improvement of ED in the first three
months of dialysis treatment, before returning to previ-
ous levels (26). Wein and Van Arsdalen have identified a
list of drugs most commonly used by the general popu-
lation that may be able to determine ED, some of which
are frequently used in dialysis patients (27). 
In our study, the focus was on beta-blockers, but no sig-
nificant correlation between drug intake and onset of ED
was found. In the literature there is only one study that
demonstrates that the use of beta blockers is a significant
risk factor for developing ED in dialyzed patients. 
As for the evaluation of the hormone profile, a condition
of hyperprolactinemia was found in 25% of the sample,
according with the data in the literature ranging between
20 and 40%. This however does not seem to affect the
appearance of ED, but we need to point out the existence
of studies which show that there exists a connection
between the condition of hyperprolactinemia and
decreased libido (28). A condition of important
hypotestosteronemia (T < 250 ng/dl) was seen in almost
60% of the sample, which is quite concordant with the
literature (29). 
However, it remains disputed why this condition
appears. According to some authors, the reason might be
the uremia, that, like with other organs (eg, uremic car-
diomyopathy, uremic gastritis), leads to a dysfunction of
the complex mechanisms of regulation of the hypothala-
mic-pituitary-gonadal axis, caused especially by changes
in the opioid pathway (30); according to other authors
the substances used in dialysis membranes produce a
functional and histological change in the gonads (31). A
third hypothesis is based on the loss of most steroid pre-
cursors during dialysis procedures. Finally there is one
last hypothesis that claims that the decreased blood level
of zinc may be the cause (32). 
Our study also shows that hypotestosteronemia is an
effective risk factor for the onset of ED. The data in the
literature concerning this statement are very discordant
and very often this is determined by the different value
of testosterone serum concentrations considered patho-
logical by different authors. In recent years, however, the
tendency is to reaffirm an important role of testosterone
in erectile mechanisms: in fact, there are frequent cases
of ED refractory to PDE-5 inhibitors that happen to be
cases of unknown hypogonadism (33). 
The records obtained from end-stage CKD patients treat-
ed with renal transplantation, are similar to those
obtained from the group of patients undergoing dialysis.
Also in this group the prevalence of ED is higher, it
appears earlier and is more severe than in the group of
patients not affected by CKF. We would underline that
there is a slightly lower prevalence (65% vs 70%) of ED
in transplanted patients compared with dialyzed ones,
but the difference is not so blatant and numerous com-
parative studies showed that the prevalence of ED before
and after renal transplantation remains the same or the
improvement is only limited to a small percentage of
cases (34, 35). 
As well as in dialyzed patients, in transplanted patients
advanced age and diabetes are major risk factors for the
development of ED. Beta blockers intake and hyperpro-
lactinemy do not seem to affect the onset of ED. 
The new element is represented by a reduction in the
prevalence of hypotestosteronemia (37% vs 59%). 
This may suggest, on one hand, that the uremia improve-
ment obtained by transplant solves at least in part the
condition of hypogonadism, and on the other hand that
dialysis treatment is actually one of the causes of the
hypotestosteronemia. 
Hypotestosteronemia still has a much higher prevalence
in these patients rather than in subjects in apparent good
health (37% vs 12%) of the same age. This is probably
due to the fact that uremia and dialysis treatment pro-
duce not only a functional damage, but also an anatom-
ic chronic damage at gonads. Another hypothesis is that
the immunosuppressive therapy to which the transplant-
ed patients are subjected, determines a disendocrine dis-
ease preventing at least in part, the resolution of the
hypogonadism. In the end, the hypotestosteronemia
does not appear to be a significant risk factor for the
onset of ED in the transplanted patients therefore, prob-
ably, the ED is caused by the vascular and neuropathic
chronic damage produced by pre-existing chronic ure-
mia. Many recent publications have pointed out the use-
fulness and the safety of the treatment. 
A study by Sharma in 2006 and one by Cofan in 2002
have shown effectiveness of therapy in approximately
85% of the subjects and at the same time no change in
blood concentration of calcineurin inhibitors (36, 37).
In patients on hemodialysis, as well as in transplanted
patients, the elective drugs for treatment of ED are the
PDE5 inhibitors. 
A review of the 2006 shows their effectiveness and safe-
ty. However, the number of patients not responding to
the therapy is higher than that found in transplant recip-
ients. As our study demonstrated, hypogonadism is a
major risk factor for ED in dialyzed patients. 
For this reason, in refractory cases in which the hypo -
testosteronemia is diagnosed, it is necessary to support a
PDE5 inhibitor therapy with transdermal hormone
replacement therapy (5 mg/day) or intramuscular (250
mg every 3-6 weeks). Recent studies in fact show a syn-
ergistic role of testosterone and PDE-5 inhibitors: in fact,
testosterone induces an increased expression of iNOS in
the corpora cavernosa.
CONCLUSIONS
ED in patients with end stage CKF continues to have a
strong prevalence, in cases both where the patients are
undergoing dialysis or have received transplants. In the
literature this issue is often not considered, or sufficient-
ly so, with the direct consequence that the ED often ends
up being misunderstood and therefore not treated in
these patients. In our experience during this study it is
evident that both patients and their physicians maintain
a certain reticence on this issue, even though the patients
affected by ED say that this condition greatly impacts
their quality of life.
Our advice therefore would be to practice all the strate-
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gies (reduction of risk factors and pharmacological
approach) that could counteract the ED. Age, obviously,
is not a modifiable factor, but an effective diabetic con-
trol is possible, and both the kidney basic functionality
and erection would benefits from that. Our study also
shows that the hypotestosteronemia is a genuine risk fac-
tor for the onset of ED in patients with end-stage chron-
ic renal failure. Based on the records of prevalence of
hypogonadism which is significantly lower among trans-
plant recipients, the kidney transplantation appears to
have a protective role of the sexual capabilities of these
patients. 
This may suggest, on one hand that the improvement of
uremia obtained by transplant solves at least in part the
condition of hypogonadism, or on the other, that dialy-
sis treatment is actually one of the causes of the
hypotestosteronemia. 
Finally, we pointed out that the therapy of hypogo-
nadism, not only helps to solve the ED so improving the
quality of life for patients, but also could increase life
expectancy. In fact, there is increasingly more scientific
evidence indicating that low testosterone serum level
correlates with increased cardiovascular accidents,
increased central obesity, metabolic syndrome, bone
fragility which would reduce life expectancy.
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